[go: up one dir, main page]

CN1326525C - 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation - Google Patents

10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation Download PDF

Info

Publication number
CN1326525C
CN1326525C CNB2004100846473A CN200410084647A CN1326525C CN 1326525 C CN1326525 C CN 1326525C CN B2004100846473 A CNB2004100846473 A CN B2004100846473A CN 200410084647 A CN200410084647 A CN 200410084647A CN 1326525 C CN1326525 C CN 1326525C
Authority
CN
China
Prior art keywords
parts
preparation
hydroxycamptothecin
liposome
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004100846473A
Other languages
Chinese (zh)
Other versions
CN1650864A (en
Inventor
施斌
裴元英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to CNB2004100846473A priority Critical patent/CN1326525C/en
Publication of CN1650864A publication Critical patent/CN1650864A/en
Application granted granted Critical
Publication of CN1326525C publication Critical patent/CN1326525C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The present invention belongs to the field of a medicinal preparation. The present invention relates to 10-hydroxy camptothecin long cyclic liposome, a freeze dried preparation of the long cyclic liposome and a preparation method thereof. The present invention discloses a method of the preparation, which can be industrially implemented. Phosphatidyl choline/soybean phospholipid or hydrolecithin and lipid modified by PEG are used as membrane material; cholesterol is used as a stabilizing agent; trehalose dihydrate or sucrose is used as a freeze dried protective agent; ethanol and methylene chloride are used as solvent. The 10-hydroxy camptothecin long cyclic liposome of the present invention has the good antitumoral effect and has the advantages of low toxicity, good patients' tolerance, water solubility and stability enhancement, and low relative cost.

Description

10-hydroxycamptothecine long circulating liposomes and lyophilized formulations thereof
Technical field
The invention belongs to field of pharmaceutical preparations, relate to the 10-hydroxycamptothecine long circulating liposomes, lyophilized formulations of long circulating liposomes and preparation method thereof.
Background technology
(Hydrocamptothecin HCPT) is the strongest micro-alkaloid of antitumaous effect in the similar antitumor monomer that extracts in the 60-70 age in this century to 10-hydroxycamptothecine from Chinese Fructus seu radix camptothecae acuminatae (Fructus Camptothecae Acuminatae), be S-phase specificity cancer therapy drug.Its anticancer mechanism of the pharmacological research of system is for suppressing Topo I, clinical ascitic type liver cancer, tumor of head and neck, gastric cancer and bladder cancer and the leukemia of mainly applying to, the toxic reaction of HCPT mainly shows the inhibition of urinary system, digestive system and hemopoietic function etc., but its toxicity is starkly lower than camptothecine, particularly the urinary system reaction is few, easily is accepted clinically.At present, the subject matter that this medicine exists has: the half-life short (5min-1h), need repetitively administered, so toxic and side effects is bigger; Fat-soluble strong, and the active anticancer reduction by 90% of making the water solublity sodium salt; Poor stability, the lactonic ring of medicine are lost pharmacologically active to light, thermo-responsive after the lactonic ring open loop.At present, domesticly clinically be form (patent 02138930.6 and 02114913.5) with the salt of the open loop of HCPT with preparation, such preparation drug effect significantly descends, and toxicity increases, thereby has limited clinical practice.Research is one of main direction of its research to the 10-hydroxycamptothecine novel form at present.
The half-life of 10-hydroxycamptothecine is short, only be about 5min-1h, on the treatment characteristics, such medicine is in concentration that affects the treatment and time factor, time is principal element, belong to the time-dependent medicine, be mainly used in poky tumor treatment, so this mechanism of action requires its long-term prescription.Many studies show that, administration nano-drug administration system have good targeting and slow releasing function, are particularly conducive to the anticancer therapy of such time-dependent sexual type medicine and the fast medicine of metabolism.Employing absorption-packs such as domestic Zhang Zhi's honor have prepared the 10-hydroxycamptothecine PBCA nanoparticle of polyvinyl pyridine alkane ketone bag quilt, experimental results show that this medicine carrying nanoparticle has tangible liver targeting and slow releasing function.Domestic patent 03152834.1 discloses the Emulsion and the Emulsion of 10-hydroxycamptothecine, has increased stability of drug, has changed medicine distribution in vivo, has improved the curative effect of medicine.Domestic patent 01138252.X has prepared 10-hydroxycamptothecine glucosan nanoparticle, 01133700.1 prepared polylactic acid nano particle, 03113179.4 prepared the liposome of HCPT, these preparations show to have the higher selectivity of reticuloendothelial system (liver, spleen etc.), better to treatment hepatocarcinoma, but not in other tumors of reticuloendothelial system, such preparation does not only have targeting, has also increased the toxicity of medicine to reticuloendothelial system as if lesions position.
Summary of the invention
The object of the present invention is to provide the long circulating liposomes of 10-hydroxycamptothecine and the freeze-dried preparation of long circulating liposomes.Preparation of the present invention can disperse with normal saline or glucose injection, is used for intravenously administrable.
Characteristics of the present invention are to use the lipid of PEGization to come modified liposome, and it is bigger to solve the traditional liposomal particle diameter on the one hand, poor stability, the problem of easily leakage, fusion and lyophilization difficulty; Surface of liposome is modified by PEG, form a kind of spatial " conformation cloud ", the absorption of opsonic identification and plasma protein in the prevention blood, reduce liposome engulfing by reticuloendothelial system, thereby the removing speed of liposome is slowed down, and residence time prolongs in the blood, helps it and enters tumor tissues, and promote its infiltration and delay effect (EPR effect), thereby reach cancer target and efficacy enhancing and toxicity reducing effect to tumor tissues.
The lipid of PEGization involved in the present invention comprises the phospholipid such as the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two of PEGization; Block or friendship graft copolymer class such as polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA) etc.; Surfactant-based as poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene hydrogenated Oleum Ricini (Cremophor) etc.Its common trait is that an end is hydrophilic Polyethylene Glycol, because PEG has hydrophilic and pliability preferably, is proved to be best face finish material at present; The other end then is lipophilic hydrophobic side, can well be embedded in the double-layer of lipoid of liposome to form lipid film jointly with phospholipid.
The present invention carries out around the preparation of 10-hydroxycamptothecine, but also can be used for other water insoluble camptothecins such as camptothecine, 9-aminocamptothecin, 9-nitrocamptothecin etc., the 10-hydroxycamptothecine of treatment cancer prepared in accordance with the present invention is compared with existing clinical dosage form, toxicity is less and more stable, and its anti-tumor activity improves greatly.
Purpose of the present invention is achieved through the following technical solutions:
The 10-hydroxycamptothecine long circulating liposome preparation is characterized in that following weight proportion medicine is a raw material: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, lipid 10-100 part, cholesterol 2-50 part, trehalose or sucrose 10-400 part that PEG modifies.
Described phospholipid is lecithin, soybean phospholipid or hydrogenated soya phosphatide;
Described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two, polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA), poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene castor oil ether (Cremophor) wait one of them or any combining form.
Technical solution of the present invention also relates to the preparation method of described 10-hydroxycamptothecine long circulating liposome preparation, it is characterized in that following weight proportion medicine is a raw material: 10-hydroxycamptothecine 1-5 part, phosphatidase 11 0-100 part, cholesterol 2-50 part, trehalose or sucrose 10-400 part.The process preparation of freeze-dried preparation by may further comprise the steps: phospholipid, cholesterol and HCPT are dissolved in certain mixed organic solvents, remove organic solvent, constant temperature removes and desolvates, vacuum drying, adding is dissolved with in the trehalose or aqueous sucrose solution of aforementioned proportion, after the aquation dissolving, available ultrasound wave or high pressure dispersing emulsification machine are handled, divide in the container of packing into, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Seal or can use nitrogen, helium, carbon dioxide or argon during gland.
Described phospholipid is lecithin, soybean phospholipid or hydrogenated soya phosphatide or wherein any two kinds of mixture.
Described PEGization lipid is the hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) of Polyethylene Glycol-two, polyethylene glycol-caprolactone (PEG-PCL), polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA), polyethylene glycol-lactic acid (PEG-PLA), polyethylene glycol-cetyl cyanoacrylate (PEG-PHDCA), poloxamer 188 (Pluronic F68), polyoxyethylene fatty acid ester class (Mrij), polyoxyethylene fatty acid ether (Brij), polyoxyethylene hydrogenated Oleum Ricini (Cremophor) wait one of them or any combining form.
It is 40-60 ℃ that used constant temperature is removed solvent temperature.
Used organic solvent can be dichloromethane, chloroform, ethanol, methanol, oxolane, dimethyl sulfoxide and composition thereof.
Used hydration temperature can be 10-80 ℃.
Used freeze drying protectant also can be trehalose, sucrose, glucose, lactose, dextran, mannitol, F68 (poloxamer 188) and composition thereof.
Beneficial effect of the present invention shows: can stablize the Alpha-hydroxy lactonic ring of 10-hydroxycamptothecine, it is existed with closed loop, increase stability of drug; Can increase the water solublity of 10-hydroxycamptothecine, improve the suitable pin of injection; Can increase the half-life of 10-hydroxycamptothecine, increase its blood circulation time; Can improve the effect of target tumor, improve the curative effect of medicine, reduce toxicity; The lyophilized preparation of the present invention's preparation aquation again forms liposome solutions, increases stability of formulation; The present invention adopts membrane process preparation, technology simple possible.
Description of drawings
The release in vitro of the liposome that Fig. 1 .Brij-40 modifies: discharge percentage rate-time graph.
Fig. 2. the particle size distribution figure of liposome.
Fig. 3. with haemoconcentration (cpm/0.5ml) time graph of the lipid-modified liposome of various PEGization.
The specific embodiment
Embodiment 1.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, hard ester acyl PHOSPHATIDYL ETHANOLAMINE (PEG-DSPE) 5g of Polyethylene Glycol-two is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.
Embodiment 2.
With 10-hydroxycamptothecine 2g, phosphatidase 15 0g, cholesterol 10g, polyethylene glycol-caprolactone (PEG-PCL) 10g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the aqueous trehalose of 100g aquation 30min, handle with the high pressure dispersing emulsification machine, promptly get the long circulating liposomes solution of 10-HCPT.
Embodiment 3.
With 10-hydroxycamptothecine 4g, phosphatidase 15 0g, cholesterol 20g, polyethylene glycol-Acetic acid, hydroxy-, bimol. cyclic ester lactide (PEG-PLGA) 8g is dissolved in dichloromethane: in the ethanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the mannose and sucrose water (1: 1) solution of 70g aquation 30min, with handling, promptly get the long circulating liposomes solution of 10-HCPT with the high pressure dispersing emulsification machine.
Embodiment 4.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 25g, polyethylene glycol-lactic acid (PEG-PLA) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the mannose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
Embodiment 5.
With 10-hydroxycamptothecine 4g, phosphatidase 15 0g, cholesterol 15g, poloxamer 188 (Pluronic F68) 10g is dissolved in dichloromethane: in the ethanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
Embodiment 6.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene fatty acid ester (Mrij-100) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.
Embodiment 7.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene fatty acid ether (Brij-40) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.Again after disperseing with normal saline, be suspended from the bag filter, be positioned in the commentaries on classics basket of digestion instrument.At 37 ℃, constant temperature vibration under the 60rmin-1 condition, different time points sampling 0.5ml, add 0.5ml release medium (the PBS buffer of pH7.4) simultaneously, sample carries out acidify through the 10ulHCL of 0.1M, and sample introduction 20ul carries out HPLC and measures, and calculates cumulative release percent (%).See Fig. 1.
Embodiment 8.
With 10-hydroxycamptothecine 1g, phosphatidase 15 0g, cholesterol 15g, polyoxyethylene hydrogenated Oleum Ricini (Cremophor) 5g is dissolved in chloroform: in the methanol (2: 1), rotary evaporation is removed organic solvent, vacuum drying, adding is dissolved with in the trehalose and sucrose water (1: 1) solution of 100g aquation 30min, use ultrasonic Treatment, promptly get the long circulating liposomes solution of 10-HCPT.The liposome branch is packed in the container, lyophilization, the lyophilizing long circulating liposome preparation of 10-hydroxycamptothecine.Logical nitrogen seals.Again after disperseing with normal saline, measure particle diameter, see Fig. 2 with Nicomp TM 380ZLS granularity and zeta potentiometer.
Embodiment 9.
HCPT's 125The I labelling adopts the Iodogen method.The HPCT that takes by weighing 3.3mg is dissolved in the 1mL methanol, therefrom gets 100 μ L solution and places the Iodogen pipe, adds 1～2mCi Na 125I is transferred to little centrifuge tube behind the slight oscillating reactions 5min, and the effective 300 μ L redistilled water washed twice of Iodogen are incorporated in the small test tube.HPLC identifies and to show, 125The mark rate of I-HCPT is about 97%.
Get 24 of SD rats, be divided into 8 groups at random.Press 4.6875uCi/10g single dose tail vein injection HCPT aqueous solution for first group, second and third, four, five, six, seven groups press the 4.6875uCi/10g single dose respectively and inject the nanometer liposomes of modifying with Mrij-100, F68, Cremorphor RH 40, Mrij-40, F127, PEG-DSPE, get blood 0.5ml in the optical fundus respectively at 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h after the administration, gamma counter reads radiocounting.See Fig. 3.

Claims (6)

1.一种10-羟基喜树碱长循环脂质体制剂，其特征是以下述重量配比成分为原料制成冻干制剂：10-羟基喜树碱1-5份，磷脂10-100份，PEG修饰的脂质10-100份，胆固醇2-50份，海藻糖或蔗糖10-400份，所述的PEG化脂质为聚乙二醇-二硬酯酰磷脂酰乙醇胺，聚乙二醇-聚己内酯，聚乙二醇-聚乙交酯丙交酯，聚乙二醇-聚乳酸，伯洛沙姆188，聚氧乙烯脂肪酸酯类，聚氧乙烯脂肪酸醚或聚氧乙烯甲基蓖麻油醚其中之一或任何组合形式。1. A 10-hydroxycamptothecin long-circulation liposome preparation is characterized in that the freeze-dried preparation is made from the following weight ratio components: 1-5 parts of 10-hydroxycamptothecin, 10-100 parts of phospholipids , 10-100 parts of PEG-modified lipids, 2-50 parts of cholesterol, 10-400 parts of trehalose or sucrose, and the PEGylated lipids are polyethylene glycol-distearoylphosphatidylethanolamine, polyethylene glycol Alcohol-polycaprolactone, polyethylene glycol-polyglycolide-lactide, polyethylene glycol-polylactic acid, poloxamer 188, polyoxyethylene fatty acid esters, polyoxyethylene fatty acid ethers or polyoxyethylene One or any combination of methyl castor oil ether. 2、根据权利要求1的10-羟基喜树碱长循环脂质体制剂，其特征是所述磷脂为卵磷脂、大豆磷脂或氢化大豆磷脂及其任何组合形式。2. The 10-hydroxycamptothecin long-circulation liposome preparation according to claim 1, characterized in that the phospholipid is lecithin, soybean phospholipid or hydrogenated soybean phospholipid and any combination thereof. 3、根据权利要求1的10-羟基喜树碱长循环脂质体制剂的制备方法，其特征是以下述重量配比成分为原料：10-羟基喜树碱1-5份，磷脂10-100份，PEG修饰的脂质10-100份，胆固醇2-50份，海藻糖或蔗糖10-400份，将10-羟基喜树碱、磷脂、胆固醇按上述比例溶于二氯甲烷：甲醇2∶1中，恒温除去溶剂，加入溶有上述比例计算的海藻糖或蔗糖水溶液中，溶解后，超声或高压匀浆处理，分装入容器内，冷冻干燥，得10-羟基喜树碱的冻干长循环脂质体制剂。3, according to the preparation method of the 10-hydroxycamptothecin long-circulation liposome preparation of claim 1, it is characterized in that the following weight ratio components are used as raw materials: 1-5 parts of 10-hydroxycamptothecin, 10-100 parts of phospholipids 10-100 parts of PEG-modified lipids, 2-50 parts of cholesterol, 10-400 parts of trehalose or sucrose, 10-hydroxycamptothecin, phospholipids, and cholesterol are dissolved in dichloromethane according to the above ratio: methanol 2: In 1, remove the solvent at constant temperature, add trehalose or sucrose aqueous solution dissolved in the above ratio, after dissolving, perform ultrasonic or high-pressure homogenization treatment, divide into containers, and freeze-dry to obtain the freeze-dried product of 10-hydroxycamptothecin Long-circulating liposomal formulations. 4.根据权利要求3的方法，其特征是所述磷脂选自卵磷脂、大豆磷脂或氢化大豆磷脂。4. The method according to claim 3, characterized in that said phospholipid is selected from lecithin, soybean lecithin or hydrogenated soybean lecithin. 5.根据权利要求3的方法，其特征是所述恒温除去溶剂的温度是40-60℃。5. The method according to claim 3, characterized in that the temperature of said isothermal solvent removal is 40-60°C. 6.根据权利要求3的方法，其中冷冻后通入氮气、氦气或氩气，然后进行轧盖或封口。6. The method according to claim 3, wherein after freezing, nitrogen, helium or argon is fed, and then capping or sealing is carried out.
CNB2004100846473A 2004-11-26 2004-11-26 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation Expired - Fee Related CN1326525C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100846473A CN1326525C (en) 2004-11-26 2004-11-26 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100846473A CN1326525C (en) 2004-11-26 2004-11-26 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation

Publications (2)

Publication Number Publication Date
CN1650864A CN1650864A (en) 2005-08-10
CN1326525C true CN1326525C (en) 2007-07-18

Family

ID=34869244

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100846473A Expired - Fee Related CN1326525C (en) 2004-11-26 2004-11-26 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation

Country Status (1)

Country Link
CN (1) CN1326525C (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100531720C (en) * 2006-07-07 2009-08-26 中国科学院上海药物研究所 A kind of hydroxycamptothecin long circulation nano lipid carrier and preparation method thereof
CN101744767B (en) * 2008-12-05 2013-02-13 中国人民解放军军事医学科学院毒物药物研究所 Thermal sensitive liposome preparation containing camptothecin antineoplastic agents
ES2547698T3 (en) * 2009-12-03 2015-10-08 Jiangsu Hengrui Medicine Co., Ltd. Irinotecan liposome or its hydrochloride and method of preparation thereof
CN105777770B (en) * 2014-12-26 2018-05-25 中国人民解放军第二军医大学 A kind of the 7-Ethyl-10-hydroxycamptothecin compound and its long circulating liposome of saturated long chain fatty acid modification
CN106109415B (en) * 2016-07-26 2019-01-29 金华市人民医院 A kind of load camptothecin antineoplastic agents liposome, preparation method and applications
CN115721610B (en) * 2021-08-27 2024-10-25 沈阳药科大学 A 7-ethyl-10-hydroxycamptothecin compound liposome and its preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160344A (en) * 1994-10-14 1997-09-24 药制品美国公司 Lyophilizate of Lipid complex of water insoluble camptothecins
CN1376468A (en) * 2002-03-01 2002-10-30 深圳万乐药业有限公司 Freeze dried hydroxy camptothecin powder for injection and its preparing process
CN1397280A (en) * 2002-08-15 2003-02-19 黄石李时珍药业集团武汉李时珍药业有限公司 Freeze dried hydroxycamptothecin powder injection and its preparing process
CN1537534A (en) * 2003-04-14 2004-10-20 江苏省药物研究所 Liposome of 10-hydroxycamptothecine, and its prepn. method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1160344A (en) * 1994-10-14 1997-09-24 药制品美国公司 Lyophilizate of Lipid complex of water insoluble camptothecins
CN1376468A (en) * 2002-03-01 2002-10-30 深圳万乐药业有限公司 Freeze dried hydroxy camptothecin powder for injection and its preparing process
CN1397280A (en) * 2002-08-15 2003-02-19 黄石李时珍药业集团武汉李时珍药业有限公司 Freeze dried hydroxycamptothecin powder injection and its preparing process
CN1537534A (en) * 2003-04-14 2004-10-20 江苏省药物研究所 Liposome of 10-hydroxycamptothecine, and its prepn. method

Also Published As

Publication number Publication date
CN1650864A (en) 2005-08-10

Similar Documents

Publication Publication Date Title
CN101485629A (en) Drug delivery system and preparation method thereof
EP1539102A2 (en) Pharmaceutically active lipid based formulation of sn38
CN101653414A (en) Long-circulating solid lipid docetaxel nanoparticles and preparation method thereof
CN102784109B (en) Taxane medicines albumin nanoparticle preparation for injection and preparation method thereof
Xin et al. PLGA nanoparticles introduction into mitoxantrone-loaded ultrasound-responsive liposomes: In vitro and in vivo investigations
WO2008080369A1 (en) Steady liposomal composition
CN1840193B (en) Nanomicelle formulation of anthracycline antitumor antibiotics entrapped in PEGylated phospholipids
CN105456194A (en) Magnolol liposome and derivative preparation and preparation method thereof
CN112535676A (en) Nano-structure lipid preparation for improving adriamycin tumor active targeting and kidney protection and preparation method thereof
Gandhi et al. Current trends in niosome as vesicular drug delivery system
CN108567742A (en) SN38 lipid compositions, preparation method and use
CN104523597B (en) A kind of targeting drug administration preparation of podophillotoxines medicine
CN100423778C (en) Liposome carrier for loading antineoplastic drugs and its preparation method and application
CN102579317A (en) Cantharidin vesicles and preparation thereof and preparation methods of cantharidin vesicles and preparation thereof
CN106109415B (en) A kind of load camptothecin antineoplastic agents liposome, preparation method and applications
CN103622924B (en) A kind of docetaxel liposome and preparation method thereof
CN112972382B (en) A kind of SN-38 polymer micelle containing lipid and its preparation method and application
CN107158395B (en) Cabazitaxel phospholipid composition and preparation method and application thereof
CN1326525C (en) 10-hydroxy camptothecin long cyclic liposome and its freeze aried preparation
WO2021196659A1 (en) Glycosyl polyether compound liposome, preparation method therefor and medicine thereof
CN105726494A (en) Nanometer andrographolide suspension composition, and preparation method and application of composition
CN101322681B (en) Method for preparing nano micelle formulation of anthracene nucleus antineoplastic antibiotic
CN107126425A (en) A kind of tanshinone IIA PEG PLGA PEG nanoparticles and preparation method thereof
CN101062094B (en) Salvianolic acid long-circulation liposome and preparation method thereof
CN113908123B (en) Micelle containing taxane medicine, preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20070718

Termination date: 20101126